Loma Linda University
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Loma Linda University sits in the top decile of US sponsors by registered trial count (#138 of 15,742 sponsors by registered trial count).
Loma Linda University: 237 sponsored US clinical trials, 35 recruiting.
Loma Linda University sponsors 237 registered US clinical trials on ClinicalTrials.gov, 35 of them currently recruiting, and 154 completed. 22 of these trials are in Phase 3-4 (later-stage) and 14 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Inflammation, with 4 trials.
Top-decile sponsor footprint
Loma Linda University ranks in the top decile of sponsors by registered trial count (#138 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
154 of 186 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (82.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
237 total, page 5 of 5
A Comparative Study of Global 12 Lead Electroencephalogram to Frontal SedlineTM Electroencephalogram
NCT01256749
Esmolol or Nitroglycerin Infusion for Blood Pressure Control Prior to Cardiopulmonary Bypass (CPB) in Cardiac Surgery
NCT01212874
Arterial Pulse Waveform Contour Analysis for Intraoperative Goal Directed Therapy in Major Spine Surgery
NCT01124474
The Effects of Orally Ingesting Branched Chained Amino Acids on Delayed Onset Muscle Soreness in Diabetic Patients
NCT01211717
The Effect of Prior Muscle Activation on the Compound Muscle Action Potential (CMAP)
NCT01182558
Proton Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With HCC Exceeding San Francisco Criteria
NCT01141478
POCD in Elderly Patients Following Desflurane or Sevoflurane General Anesthesia
NCT01199913
T-Wave Alternans in Patients With Suspected Acute Coronary Syndrome
NCT01137513
Treatment of the Rotator Cuff Disease With Platelet Rich Plasma Injection
NCT01123889
Clinical Outcome Comparison Between Medial and Lateral Offset Reverse Shoulder Arthroplasty
NCT01086202
A Closer Look at the Effect of Dextrose on Postoperative Nausea and Vomiting
NCT01123837
Comparison of Tranexamic to Epsilon Aminocaproic Acid: a Prospective Analysis of Blood Conservation in Cardiac Surgery
NCT01248104
Comparison of Pulse Hemoglobin and Pleth Variability Index
NCT01602978
A Very High Fiber Diet Versus a Low-carbohydrate Diet for Weight Loss
NCT01051674
Comparison of Telemedicine Evaluation to Standard Evaluation Methods for Pre-Anesthesia Consultation
NCT01240239
Comparison of Oral Gabapentin and Pregabalin in Postoperative Pain Control After Photorefractive Keratectomy
NCT00954187
Determining the Lymphokine Activated Killer (LAK) Cytotoxicity Present in Patients Undergoing Interleukin-2 Therapy
NCT01068470
Arterial Pulse Waveform Contour Analysis for Intraoperative Goal Directed Therapy in Major Abdominal Surgery
NCT01082614
Evaluation of a Social-networking Intervention to Reduce Cancer-related Distress
NCT01976949
Effects of Peanut and Peanut Butter Consumption on Blood Lipids and Glycemic Control in Adults With Type 2 Diabetes
NCT00937222
Prevention of Postpartum Smoking Relapse in Mothers of Infants in the Neonatal Intensive Care Unit (NICU)
NCT01131156
Study of Hypofractionated Proton Beam Radiation Therapy for Prostate Cancer
NCT00831623
Azacitidine and Cisplatin in Patients With Advanced Lung or Head and Neck Cancer
NCT00901537
Transarterial Chemoembolization Versus Proton Beam Radiotherapy for the Treatment of Hepatocellular Carcinoma
NCT00857805
Assessment of the Effect of Botulinum Toxin in Extensor Digitorum Brevis Via Strain Gauge and Nerve Conduction Studies
NCT00822523
Randomized, Controlled Trial of S-adenosylmethionine in Alcoholic Liver Disease
NCT00851981
Preemptive Analgesia in Children Using Caudal Epidural Ropivacaine
NCT00616577
The Effects of Dexamethasone on the Duration of Sciatic Nerve Blocks
NCT00616603
Minimally-Invasive Cardiovascular Hemodynamic Optimization (MiCHO) Versus Early Goal-Directed Therapy (EGDT) in the Management of Septic Shock
NCT00535821
The Effect on Cognition of Terminating ECT Induced Seizures With Propofol
NCT00616759
Topical Nitric Oxide Trial in Chronic Non-Healing Wounds
NCT00823095
A Trial Comparing Prograf and Neoral Use in Kidney Transplant Recipients of Hispanic Ethnicity
NCT00983645
Proton Therapy for Early Stage Breast Cancer
NCT00614172
Plasmapheresis for Nephrogenic Fibrosing Dermopathy (NFD)/Nephrogenic Systemic Fibrosis (NSF)
NCT01078987
Sildenafil (Viagra) for the Treatment of Dyskinesias in Parkinson's Disease
NCT02162979
Chemotherapy and Proton Radiation for the Treatment of Locally Advanced Lung Cancer
NCT00614484
Proton Beam Therapy for Treatment of Hepatocellular Carcinoma
NCT00614913
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 7 |
| Phase 3 | 12 |
| Phase 4 | 10 |
Therapeutic Areas
Where Loma Linda University enrollment is open (later-stage tilt)
35 recruiting of 237 indexed (15% open); 154 completed (65%).
Phase mix: 22 late (III/IV) vs 14 early (I/II) (later-stage heavy).
Top condition: Inflammation (4 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Loma Linda University: open-pipeline peers nationwide
Peers matched on 237 registered trials and 15% open enrollment, not the therapeutic-area sidebar.
Loma Linda University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 237 trials (± recruiting share)
- Daiichi Sankyo · 236 trials · 12% recruiting
- Incyte Corporation · 239 trials · 15% recruiting
- University of Massachusetts, Worcester · 240 trials · 13% recruiting
- Henry Ford Health System · 234 trials · 18% recruiting
Sponsors near 15% open enrollment (± trial volume)
- University of Rochester · 15% recruiting · 636 trials
- Dompé Farmaceutici S.p.A · 15% recruiting · 27 trials
- Vanderbilt-Ingram Cancer Center · 15% recruiting · 189 trials
- Brown University · 15% recruiting · 231 trials
Related
What to do with this Loma Linda University page
237 registered trials is a research-attention snapshot, not an endorsement of Loma Linda University or any single study.
- 35 of Loma Linda University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Inflammation is the condition Loma Linda University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Inflammation trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Loma Linda University pipeline card: 237 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.